An all-oral regimen on a 28-day cycle¹

INQOVI dosing schedules

INQOVI is administered on a 28-day cycle for both approved indications.

INQOVI for AML

For acute myeloid leukemia (AML), INQOVI is taken as 1 tablet orally once daily on Days 1 through 5 of each 28-day cycle. Venetoclax is taken daily using a ramp-up schedule in Cycle 1 and continuous dosing in subsequent cycles. Match Day 1 of INQOVI dosing with Day 1 of venetoclax dosing for each 28-day cycle.

When using INQOVI in combination with venetoclax for newly diagnosed AML, refer to the venetoclax Prescribing Information for additional dosing and administration information.

CYCLE 1
	INQOVI		Venetoclax
WEEK 1	Once daily for 5 days without food	2 days rest	Day 1: 100 mg Day 2: 200 mg Day 3: 400 mg Days 4 to 7: 400 mg once daily
WEEK 2	-	-	400 mg once daily
WEEK 3	-	-	400 mg once daily
WEEK 4	-	-	400 mg once daily

SUBSEQUENT CYCLES
	INQOVI		Venetoclax
WEEK 1	Once daily for 5 days without food	2 days rest	400 mg once daily
WEEK 2	-	-	400 mg once daily
WEEK 3	-	-	400 mg once daily
WEEK 4	-	-	400 mg once daily

INQOVI for MDS, including CMML

For myelodysplastic syndromes (MDS), including chronic myelomonocytic leukemia (CMML), INQOVI is taken as 1 tablet orally once daily on Days 1 through 5 of each 28-day cycle, for a minimum of 4 cycles until disease progression or unacceptable toxicity.

A complete or partial response may take longer than 4 cycles.

Patients administered an IV treatment in an earlier cycle may be switched to INQOVI for subsequent cycles—but not within a cycle.

ALL CYCLES
	INQOVI
WEEK 1	Once daily for 5 days without food	2 days rest
WEEK 2	-	-
WEEK 3	-	-
WEEK 4	-	-